Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.
Qu XM, Chen Y, Zaric GS, Senan S, Olson RA, Harrow S, John-Baptiste A, Gaede S, Mulroy LA, Schellenberg D, Senthi S, Swaminath A, Kopek N, Liu M, Warner A, Rodrigues GB, Palma DA, Louie AV.
Qu XM, et al.
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1176-1184. doi: 10.1016/j.ijrobp.2020.12.001. Epub 2020 Dec 10.
Int J Radiat Oncol Biol Phys. 2021.
PMID: 33309977